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Allergy is becoming a rapidly increasing problem worldwide, and in vitro models
are frequently used to study the mechanisms behind the different types of allergic
response. The dendritic cell (DC)–T-cell model can be used to study sensitization.
However, lipopolysaccharide (LPS) is often used to maturate the DCs, but it gives rise
to a DC1 phenotype, whereas Th2-driven inflammatory diseases such as allergy are
characterized by the involvement of the DC2 phenotype. Our aim was to create a
DC2–T-cell human model (human moDC2s) to study in vitro sensitization and validate
the model using polyunsaturated fatty acids (PUFAs) that were previously shown to have
immunomodulatory properties. We found that the generated DC2s expressed OX40L
and drove naive T-cells into IL-13 production of CD4+ effector T-cells. In line with in vivo
findings, n−3 long-chain (LC)PUFA docosahexaenoic acid (DHA) effectively decreased
the DC2’s surface expression of OX40L, as well as the IL-12p40 and IL-23 cytokine
production by DC2s and subsequently lowered IL-13 production by DC2-induced
effector T-cells. Similar cytokine production effects were found with eicosapentaenoic
acid (EPA) and arachidonic acid (AA), whereas linoleic acid (LA) increased OX40L surface
expression and subsequent T-cell-derived IL-13/IFNγ ratios, suggesting an increased risk
of allergy development. Altogether, these data show that human moDC2s are able to
induce Th2-type IL-13 secretion by T-cell differentiated in the presence of these DC2s
and that this model can be differentially modulated by PUFAs. These results are in line
with previous in vivo studies using PUFAs, indicating that this model may be of use to
predict in vivo outcomes.
Keywords: DC2, Th2, DC2–T-cell model, polyunsaturated fatty acid, allergy, docosahexaenoic acid
INTRODUCTION
Th2-driven inflammatory diseases, such as allergic asthma, allergic rhinitis, and food allergy,
are rapidly increasing worldwide. According to the European Academy of Allergy and Clinical
Immunology (EAACI), in Europe, already 150 million people suffer from some type of allergy, and
around 50% of all Europeans will be allergic in 2025, with no age, social, or geographical distinctions
(1). Therefore, new strategies in allergy prevention and treatment are very much needed.
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Currently, most allergy studies are performed using preclinical
animal (mouse) models (2, 3). On the one hand, this offers a
preclinical model in which all essential immune compartments
to elicit an allergic reaction are operational. On the other hand,
the possibility to translate findings to the human situation
is not always straightforward. Often, biopsies from allergic
patients or animal’s lung or gut are used (4); however, obtaining
these specimens can be limiting the research opportunities.
In vitro allergy models often consist of single-cell models,
such as mast cells (MCs) or basophils (5). MCs or basophils
represent cells of the allergic effector phase because their
activation results in the acute allergic symptoms, meaning that
in these models, allergy treatment can be studied in vitro
rather than allergy prevention. To study allergy prevention, the
sensitization phase is of great importance. One of the most
important cellular interactions in the development of allergic
sensitization is the dendritic cell (DC)–T-cell interaction (6, 7).
DCs are important in allergen uptake at the mucosal tissue
and consequently major histocompatibility complex (MHC)
type II-associated presentation of the allergic epitopes to the
specific T-cell receptors. Depending on the phenotype of these
DCs, which can be modified by their cellular and molecular
microenvironment, they can either instruct tolerance or drive
effector T-cell responses such as Th2 cells that contribute to
the allergic sensitization cascade. Hence, the DCs and naive
T-cell interaction and consequent development of Th2 cells
provide an interesting model to preselect various bioactive
preparations aimed at allergy management. Monocyte-derived
DCs and allogeneic naive T-cell interaction studies are commonly
performed in vitro to investigate antigen presentation and T-cell
proliferation, differentiation, and related cytokine response. To
obtain mature DCs, immature monocyte-derived DC (iDCs) are
often incubated with lipopolysaccharide (LPS), which in most
cases leads to DCs that drive Th1 differentiation (8). Protocols
for the generation of DC2s, which are described to be involved in
Th2 differentiation, have been published, although these are not
many and, especially, not frequently used to study the capacity
of bioactive components for sensitization prevention (9). The
protocol described by Kalinski et al. (9) uses Staphylococcus
aureus enterotoxin B (SEB) to induce Th2 cell differentiation,
which has been described to skew Th2 differentiation by itself,
without needing the DC2 phenotype (10). Therefore, we will
further explore the potential of a DC2–T-cell model without the
use of SEB.
Many allergy prevention studies have been performed using
polyunsaturated fatty acids (PUFAs) (11). The most prominently
studied PUFA groups are omega-3 (n−3) and omega-6 (n−6) of
which n−3 α-linolenic acid (ALA) and n−6 linoleic acid (LA)
are essential in the human diet, and these can be mainly obtained
from vegetable oils, seeds, and nuts. They can be elongated
and desaturated in vivo to obtain the more bioactive long-
chain (LC)PUFA. Alternatively, these can be directly obtained
via the diet. In vivo, fish oil rich in n−3 LCPUFAs EPA
and docosahexaenoic acid (DHA) has been shown to prevent
allergic responses in allergic mouse (12, 13) and guinea pig
(14) models. In vitro and ex vivo, n−3 PUFAs EPA and DHA
inhibited costimulatory molecules CD80 and CD86 on DCs and
reduced DC inflammatory cytokine production (15, 16), T-cell
proliferation (17, 18), and response to DCs (19). Furthermore,
n−6 PUFA AA has mostly been studied in the effector phase.
n−6 PUFAs were shown to enhance MC TNFα production and
IgE-mediated degranulation (20, 21), which was also observed
in vivo (22). Of note, the majority of the DC–T-cell studies
published were performed in LPS-stimulated DCs. Therefore, the
current study aimed to establish an in vitro DC2–T-cell model to
more effectively investigate the sensitization phase, validated by
investigating the immunomodulatory effects of PUFAs, including
n−6 PUFAs LA and AA as well as n−3 PUFAs ALA, EPA,
and DHA.
MATERIALS AND METHODS
Monocyte and T-Cell Isolation
Primary human monocytes were isolated from buffy coats from
healthy donors (Sanquin, Nijmegen, The Netherlands). Before
sample collection, a written consent was obtained. Buffy coats
were diluted 1:1 with phosphate-buffered saline (PBS) + 2%
fetal bovine serum (FBS) (HyCloneTM Fetal Bovine Serum, Fisher
Scientific, Loughborough, UK) and loaded onto Greiner Bio-
OneTM LeucoSEPTM Polypropylene Tubes to obtain peripheral
blood mononuclear cells (PBMCs). After being washed, the cells
were diluted inMACS buffer, and a CD14microbead kit was used
to isolate themonocytes according to themanufacturer’s protocol
(Miltenyi Biotec, Leiden, The Netherlands). Naive CD4+ T-cells
were isolated from the flow through using a negative selection.
A naive CD4+ T Cell Isolation Kit, containing a cocktail of
biotinylated CD45RO, CD8, CD14, CD15, CD16, CD19, CD25,
CD34, CD36, CD56, CD123, anti-TCRγ/δ, anti-HLA-DR, and
CD235a (glycophorin A) antibodies (Miltenyi Biotec, Leiden,
The Netherlands), was used. All cells were frozen in 1:1 FBS and
FBS with 20% dimethyl sulfoxide (DMSO) and stored at −80◦C
until further use.
Dendritic Cell Differentiation and
Polyunsaturated Fatty Acid Treatment
iDCs were obtained by culturing primary monocytes for 6
days in a 24-well plate in Iscove’s Modified Dulbecco’s Medium
(IMDM, Gibco Thermo Fisher, Landsmeer, The Netherlands)
with 10% FBS and 1% p/s in the presence of 30 ng/ml of IL-
4 (Sigma Aldrich, Zwijndrecht, The Netherlands) and 50 ng/ml
of granulocyte-macrophage colony-stimulating factor (GM-CSF)
(R&D Systems, Minneapolis, USA). To differentiate into DC2,
a maturation mix containing 50 ng/ml of TNFα (Miltenyi
Biotec, Leiden, The Netherlands), 25 ng/ml of IL-1β (Merck
Millipore, Amsterdam, The Netherlands), 100 U/ml of IL-6
(Miltenyi Biotec, Leiden, The Netherlands), and 1µg/ml of PGE2
(Sigma Aldrich, Zwijndrecht, The Netherlands) was used, as
described previously (9). As a control, DCs were also matured
using 100 ng/ml of LPS (γ-irradiated LPSs from Escherichia coli
O111:B4, Sigma Aldrich, Zwijndrecht, The Netherlands). For
PUFA treatment, iDCs were incubated with 75µM of vitamin
C (23) and 100µM (24) of LA, ALA, AA, DHA, or EPA (all
from Sigma Aldrich, Zwijndrecht, The Netherlands) and 20µM
of vitamin E (23), which was resuspended in the serum before
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adding to the culture medium and cells. To control for the effect
of vitamins C and E, the measurements of the NT DC2s were
also compared with DC2s treated with only vitamins C and E.
After 48 h, the iDCs were incubated for another 48 h with the
DC2 maturation mix. Subsequently, the maturated moDCs were
harvested and stained for flow cytometry, and the supernatant
was stored at−20◦C for further analysis.
Dendritic Cell–T-Cell Co-culture
DC2s treated with PUFAs were cultured in a flat-bottom 96-
well plate and obtained as described above. After maturation,
cells were harvested and replated into a round-bottom 96-well
plate. Naive CD4+ T-cells were added 10:1 with 5 ng/ml of
IL-2 (Miltenyi Biotec, Leiden, The Netherlands) and 150 ng/ml
of anti-CD3 antibody (Clone CLB-T3/4.E, 1XE, Sanquin,
Amsterdam, The Netherlands). After 5 days, the cells were
harvested and stained for flow cytometry, and the supernatant
was stored at−20◦C for further analysis.
Flow Cytometry
To analyze surface marker expression of the DCs, cells
were stained with anti-CD14 (PE-eFluor 610, Thermo Fisher,
Landsmeer, The Netherlands), anti-HLA-DR (APC-eFluor 780,
Thermo Fisher, Landsmeer, The Netherlands), anti-CD11c (PE-
Cy5.5, Thermo Fisher, Landsmeer, The Netherlands), anti-
CD80 (PE-Cy7, BioLegend, Koblenz, Germany), anti-CD83
[fluorescein isothiocyanate (FITC), Thermo Fisher, Landsmeer,
The Netherlands], anti-CD86 [antigen-presenting cell (APC),
BioLegend, Koblenz, Germany], and anti-OX40L [phycoerythrin
(PE), BioLegend, Koblenz, Germany] and analyzed using a
CytoFLEX flow cytometer (Beckman Coulter, Woerden, The
Netherlands). Cell viability in DCs was determined using 7AAD
dye (BD Pharmingen, San Jose, CA).
Enzyme-Linked Immunosorbent Assay
In the supernatant of the matured moDCs, IL-12/IL-23
(p40) was measured according to the manufacturer’s protocol
(BioLegend, Koblenz, Germany). As such, IL-13, IFNγ, and
IL-10 (from BioLegend, Koblenz, Germany) were determined
in the supernatant of the DC–T-cell co-cultures. All samples
were measured using a Tecan Infinite 200PRO (Tecan,
Männedorf, Switzerland).
LEGENDplex
To further investigate cytokine production of the DC2s,
LEGENDplex a panel for Human Macrophage/Microglia,
was used, according to the manufacturer’s protocol
(BioLegend, Koblenz, Germany). Cytokines in the Human
Macrophage/Microglia panel included IL-12p70, TNFα, IL-6,
IL-4, IL-10, IL-1β, arginase, TARC, IL-1RA, IL-12p40, IL-23,
IFNγ, and IP-10. All samples were measured using a CytoFLEX
flow cytometer (Beckman Coulter, Woerden, The Netherlands),
and data were analyzed using the BioLegend LEGENDplex
cloud-based software.
Cytokine Ratio Calculations
To analyze the balance of the different cytokines produced as
a reflection of T-cell subsets, the ratios were calculated of the
normalized data. For each individual donor, the T-cell-derived
production of IL-13, IFNγ, or IL-10 of each PUFA treatment
was divided by the intrinsic production of the T-cells exposed to
untreated DC2s. The production of the control condition was set
to 1 for each cytokine. Then, IL-13/IFNγ ratios were calculated
by dividing the means of the IL-13 production by the means of
the IFNγ production for each individual donor. Similarly, we
calculated the IL-13/IL-10 and IFNγIL-10 ratio.
Statistics
All experiments were repeated at least three times independently
with different donor cells (n= independent biological replicates).
Surface marker expression of iDCs, DC1s, and DC2s were n
= 3. Surface marker expression of DC2s + PUFAs was n = 5.
All LEGENDplex and ELISA experiments were n = 5, except
for IL-13, which was n = 7. Statistical analyses were carried
out using IBM SPSS Statistics 23. All parameters are presented
as means ± SEM. Outliers were calculated by determining Q1
and Q3 of the dataset, thereby defining the interquartile range
(IQR). Subsequently, the L-bound and U-bound were calculated
by subtracting (1.5 ∗ IQR) from the Q1 (L-bound) or adding (1.5
∗ IQR) to the Q3 (U-bound). Outliers were defined as values <L-
bound or >U-bound and removed from the dataset. Outliers
were n = 5 in total, randomly divided over the dataset and
groups. A mixed linear model, based on a repeated measures
ANOVA, with a Bonferroni post-hoc to correct for multiple
comparisons was used to assess the parameters for significance
if p < 0.05 (p < 0.1 is considered as trend), where different
treatments on the same donor cells within one experiment were
considered as paired data. Within each experiment, Bonferroni
post-hoc tests were performed on selected groups, and all groups
were only compared with the non-treated (NT) DC2 control.
Graphs were plotted using GraphPad Prism 8.
RESULTS
DC2 Surface Marker Expression
DC2 cells were characterized by comparing their surface marker
expression to iDCs and DC1s, where OX40L was used as a
marker for DC2s. Immature DCs did not express much CD14,
which is lost upon transition from monocyte to DCs. iDCs
did already express DC surface markers HLA-DR, CD11c, and
CD86, and to some extent CD80 and CD83 (Figure 1). CD86
was significantly higher in DC2s compared with iDCs (p= 0.04).
CD80 and CD83 were significantly higher in DC1s (p < 0.001
and p = 0.01, respectively) and DC2s (p < 0.001 and p = 0.003,
respectively) compared with iDCs. CD83 was significantly higher
in DC2s compared with DC1s (p < 0.001), indicating a different
phenotype ofmaturation. Finally, OX40Lwas significantly higher
in DC2s compared with iDCs and DC1s (50.8 ± 4.4%, 5.7 ±
3.0%, and 7.9 ± 2.9%, p < 0.001, respectively), showing that the
used cytokine mixture was capable of phenotypically inducing
DC2 maturation as indicated by surface marker expression.
DC2 Cytokine Production
To further investigate the differences between DC2s and
DC1s, 13 different cytokines were measured in the supernatant
after 48 h of maturation using the Macrophage/Microglia
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FIGURE 1 | Percentage of DC surface marker expression on iDCs, DC1s, and
DC2s as measured by flow cytometry. Percentages indicate the frequency of
cells showing surface marker expression of total cells measured. Means ±
SEM. N = 3 independent donors. (A) Significantly different from iDCs. (B)
Significantly different from DC1s. DC, dendritic cell; iDCs, immature
monocyte-derived DCs.
TABLE 1 | Cytokines produced by DC2s vs. DC1s as measured by
LEGENDplex analyses.
Cytokine DC2 DC1 p-value
IL-12p70 n.d. n.d. -
TNFα 13.6 ± 1.9 3.3 ± 1.1 0.004**
IL-6 7.4 ± 2.0 17.6 ± 8.0 0.27
IL-4 0.2 ± 0.1 0.4 ± 0.2 0.52
IL-10 (pg/ml) 2.0 ± 0.9 70.0 ± 50.0 0.25
IL-1β 9.1 ± 1.6 0.003 ± 0.0007 0.005**
Arginase 74.1 ± 5.0 79.8 ± 9.9 0.67
TARC 2.3 ± 0.1 2.1 ± 0.2 0.23
IL-1RA 12.6 ± 2.4 16.1 ± 1.1 0.31
IL-12p40 6.2 ± 1.7 6.8 ± 3.4 0.76
IL-23 (pg/ml) 30.0 ± 9.0 5.0 ± 3.0 0.04*
IFNγ n.d. n.d. -
IP-10 (pg/ml) 2.0 ± 1.0 30.0 ± 7.0 0.03*
Values are presented in ng/ml, unless stated differently. Means ± SEM. n.d. indicates not




LEGENDplex. DC2s produce significantly more TNFα, IL-
1β, and IL-23 than do DC1s (Table 1). Furthermore, DC1s
produce significantly more IP-10, although in very low amounts.
All other measured cytokines were similarly produced. Of
note, IL-12p70 and IFNγ were undetectable in both DC2s
and DC1s.
Polyunsaturated Fatty Acids Can Modulate
Surface Marker Expression in DC2s
n−3 (ALA, EPA, andDHA) and n−6 (LA and AA) PUFAs, which
have been previously described to affect surface expression on
LPSmaturatedDCs (15, 16), were selected to studymodulation of
surface marker expression. As vitamins C and E were to be added
to avoid lipid oxidation of the PUFAs, a medium containing only
these vitamins was taken along as the proper control. Viability
staining (7AAD) indicated that all cells were viable after PUFA
treatment (no toxicity and cell death as compared with that of
the control, data not shown). The surface expression values of
the measured markers can be found in Table 2.
NT DC2s and vitamin-treated DC2s were similar in all
different markers (Table 2). On all PUFA-treated DC2s, CD14
surface expression remained low and HLA-DR, CD11c, and
CD86 expression remained high and did not differ significantly.
OX40L was significantly lower in DHA-treated DC2s compared
with the NT DC2s (p = 0.05) and showed a trend in AA-treated
DC2s (p = 0.08) (Table 2 and Figure 2A). Furthermore, LA-
treated DC2s showed an increased trend of OX40L (p = 0.06).
Finally, AA significantly lowered surface expression of CD80
and CD83 than did NT DC2s (Figures 2B,C, p = 0.02 and p =
0.04, respectively).
Polyunsaturated Fatty Acids Modulate
Cytokine Expression of DC2s
Next, we investigated the effect of PUFAs on cytokine secretion.
NT DC2s produced IL-12/IL-23 (p40), which was not affected
by vitamin treatment (Supplementary Figure 1). Whereas, ALA
did not have an effect, LA, AA, EPA, and DHA all significantly
lowered IL-12/IL-23 (p40) production by DC2s compared with
the NT [22.3 ± 5.1 vs. 12.0 ± 4.4 ng/ml, p = 0.02 (LA); 1.3 ±
0.5 ng/ml, p = 0.001 (AA); 4.1 ± 1.7 ng/ml, p < 0.0001 (EPA);
and 6.0± 2.3 ng/ml, p= 0.005 (DHA), respectively].
We further investigated cytokine production using
a LEGENDplex kit. All values can be found in
Supplementary Table 1. As also shown in the IL-12/IL-23
(p40) ELISA, all LCPUFAs affected the secretion of IL-12p40 and
IL-23. Both cytokines were significantly lower in AA-treated (p
= 0.001 and p = 0.004, respectively), EPA-treated (p = 0.002
and p = 0.008, respectively), and DHA-treated (p = 0.004 and
p = 0.007, respectively) DC2s (Figure 3). ALA significantly
lowered IL-12p40 and showed a trend for IL-23 (p = 0.03 and
p = 0.08, respectively). All other DC2 produced mediators
measured that remained unaffected by the PUFA treatment
(Supplementary Table 1).
DC2–T-Cell Activation
To validate the ability of the DC2s to drive Th2-type cytokine
secretion by CD4+ T-cells as a reflection of Th2 development
induced by the DC2, we analyzed the cytokine expression of the
T-cells that were incubated with the DC2s for 5 days. Hallmark
cytokines IFNγ (Th1), IL-13 (Th2), and regulatory IL-10 were
compared between DC2 activated T-cells and T-cells activated
by DC1s.
T-cells incubated with NT DC2s produced significantly
more IL-13 than did T-cells incubated with DC1s (1.9 ±
0.2 vs. 0.7 ± 0.07 ng/ml, p = 0.001), thereby validating our
model (Figure 4A). Of note, the DC2 themselves produced
IL-13, but in very low quantities (50 ± 0.9 pg/ml). IFNγ
production seemed to be, although not significant, slightly
lower in T-cells incubated with NT DC2s compared with
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TABLE 2 | Modulation of DC2 surface expression markers by PUFAs.
CD14 HLA-DR OX40L CD11c CD80 CD83 CD86
NT 4.4 ± 1.5 98.0 ± 0.8 49.0 ± 8.2 82.3 ± 7.2 88.1 ± 4.2 83.8 ± 4.1 93.5 ± 6.0
Vitamin 3.2 ± 0.8 96.7 ± 1.4 36.5 ± 13.1 84.7 ± 4.8 88.3 ± 2.9 83.5 ± 4.9 91.8 ± 4.9
p-value 1.00 1.00 0.92 1.00 1.00 1.00 1.00
n−6
LA 5.3 ± 4.4 99.0 ± 0.4 80.7 ± 9.5 77.4 ± 10.9 72.3 ± 3.5 79.3 ± 2.6 99.0 ± 0.8
p-value 1.00 1.00 0.06 1.00 0.67 1.00 1.00
AA 5.5 ± 2.7 93.2 ± 2.6 11.8 ± 1.6 79.5 ± 5.4 62.2 ± 4.8 58.2 ± 7.5 82.3 ± 10.5
p-value 1.00 1.00 0.08 1.00 0.02* 0.04* 1.00
n−3
ALA 1.1 ± 0.4 99.2 ± 0.2 72.1 ± 12.6 69.3 ± 9.5 69.1 ± 10.5 75.5 ± 7.1 99.3 ± 0.1
p-value 0.68 1.00 0.71 1.00 0.37 1.00 1.00
EPA 2.7 ± 0.6 93.3 ± 5.3 23.2 ± 7.6 86.0 ± 4.4 77.3 ± 9.7 76.5 ± 7.8 89.8 ± 9.3
p-value 1.00 1.00 0.32 1.00 0.76 1.00 1.00
DHA 1.3 ± 0.5 93.0 ± 4.5 10.9 ± 2.3 72.9 ± 8.0 75.0 ± 4.7 67.3 ± 7.4 90.8 ± 7.8
p-value 0.71 1.00 0.05* 1.00 0.54 0.37 1.00
Values are % as measured by flow cytometry. Means ± SEM. N = 5 independent donors.
DC, dendritic cell; NT, non-treated DC2; vitamin, vitamin-exposed DC2 control; PUFA, polyunsaturated fatty acid.
*p < 0.05.
FIGURE 2 | Percentage of surface expression of OX40L (A), CD80 (B), and CD83 (C) in DC2s treated with PUFAs as measured by flow cytometry. Means ± SEM. All
experiments are n = 5 independent donors. *p < 0.05. DC, dendritic cell; PUFA, polyunsaturated fatty acid.
DC1s (Figure 4B). It must be noted that two of the five
independent donors responded much less to LPS in IFNγ
cytokine production, resulting in a large standard deviation.
Finally, IL-10 was significantly lower in T-cells incubated with
DC2s compared with T-cells incubated with DC1s (p = 0.02)
(Figure 4C).
We calculated the ratios of hallmark cytokines IFNγ, IL-
10, and IL-13 for the various treatments (Figures 4D–F). As
expected, T-cells incubated with DC1s produce significantly less
IL-13 over IFNγ (p < 0.001) than do T-cells incubated with
untreated DC2s (Figure 4D). Furthermore, T-cells incubated
with DC1s also produce significantly more IL-10 over IL-13
(p < 0.001) than do T-cells incubated with untreated DC2s
(Figure 4E). Finally, production of IL-10 over IFNγ is similar
between treatments (Figure 4F).
Polyunsaturated Fatty Acid Modulate
Th2-Type IL-13 Response Initiated by DC2s
We investigated whether PUFAs could inhibit production of
these cytokines in our developed model. IL-13 production of T-
cells incubated with NT DC2s and vitamin-treated DC2s was
similar (Figure 5A). Furthermore, EPA and DHA significantly
lowered IL-13 production of T-cells compared with T-cells
incubated with NT DC2s [0.8 ± 0.2 ng/ml of EPA (p = 0.003)
and 0.9 ± 0.1 ng/ml of DHA (p = 0.01)]. AA showed a trend
[1.9 ± 0.2 vs. 0.9 ± 0.2 ng/ml of AA (p = 0.06)]. IFNγ
production was significantly different between T-cells incubated
with NT DC2s and vitamin-treated DC2s (11.5 ± 4. vs. 5.7
± 2.2 ng/ml, p = 0.004), indicating an effect of vitamins alone
(Figure 5B). This resulted in a significantly lowering effect of
IFNγ by LA (p = 0.04) and EPA (p = 0.007), but not ALA, AA,
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FIGURE 3 | IL-12p40 (A) and IL-23 (B) production of DC2s after incubation with different PUFAs as measured using a LEGENDplex assay. All treatments were
compared to the NT. Means ± SEM. All experiments are n = 5 independent donors. *p < 0.05; **p < 0.01; ***p < 0.001. DC, dendritic cell; PUFA, polyunsaturated
fatty acid.
and DHA. IL-10 production was similar between all treatments
(Figure 5C).
We looked into the balance of different cytokines, similar
to the comparison between T-cells incubated with DC2s and
T-cells incubated with DC1s, as a reflection of the T-cell
subjects over the different PUFA treatments (Figures 5D–F and
Supplementary Table 2). The IL-13/IFNγ ratio was significantly
higher when T-cells were incubated with DC2s treated with LA
(p = 0.003), indicating that the effector T-cells develop toward
a more Th2-type IL-13-directed response (Figure 5D). Other
treatments gave similar IL-13/IFNγ ratios compared with those
of the T-cells incubated with untreated DC2s. Interestingly, IL-
10/IL-13 ratios were all significantly higher when T-cells were
incubated with DC2s treated with AA, DHA, and EPA (all p <
0.001), indicating a higher production of regulatory cytokines
(Figure 5F). There was no difference between IL-10/IL-13 ratios
of T-cells incubated with untreated DC2s and T-cells incubated
with DC2s treated with vitamin, LA, or ALA (Figure 5E).
Moreover, all treatments gave significantly higher IL-10/IFNγ
ratios than did T-cells incubated with untreated DC2s (all p
< 0.001), indicating that vitamin can also skew the cytokine
ratio from the hallmark Th1 cytokine IFNγ toward a more
regulatory profile.
DISCUSSION
The data in this paper show that DC2s, generated from human
primary monocytes, are able to induce the secretion of IL-13
by allogeneic Th cells as a reflection of Th2 cell development.
This model can be used to analyze modulation of the DC2/T-
cell interaction with PUFAs-modified DC. LCPUFA exposure of
DCs during maturation with DC2 driving mediators resulted in
a lower surface expression of different co-stimulatory markers
for DCs (AA) or the DC2 marker OX40L (DHA). In addition,
the cytokine production of both DC2s as well as IL-13 release
by the developed T-cells and the IL-13/IFNγ ratio was reduced
by specific LCPUFA while increasing the regulatory IL-10 over
effector IL-13 and IFNγ balance. Together, this model can be
used to study a variety of new potential allergy preventing
components, which might aid in predicting in vivo outcomes.
DC–T-cell models often make use of DC1 cells that contribute
to Th1 immunity and have been maturated using LPS. However,
allergic sensitization is often characterized by the development of
Th2-driving DC2. Hence, in order to study allergy prevention in
vitro, maturation of the DCs toward a DC2 phenotype appears
more relevant. Compared with the LPS maturated DCs, DC2
cells have a higher level of OX40L on the surface, as shown
in our study and as described previously in monocyte-derived
DC2 cells from allergic patients (25). This study by Gueguen
et al. (25) extensively studied in vitro DC2s, maturated with
IL-25, IL-33, LPS, PGE2, and thymic stromal lymphopoietin,
compared with DC1s and DCregs. They observed that DC2s
produced similar levels of IL-6, IL-8, IL-10, and TNFα and lower
levels of IL-12p70 and IFNγ than did DC1s. Although IL-6
and IL-10 were, in line with these findings, similar; we found
higher TNFα levels in DC2s compared with DC1s. In the current
study, the IL-12p70 and IFNγ levels were below the detection
limit in both DC1s and DC2s. However, the DC2s did produce
detectable levels of IP-10 (CXCL10), which is closely linked to a
Th1 driving signature, and these levels were low compared with
those of DC1s. By contrast, the DC2s produced higher levels of
IL-1β and IL-23 than did DC1s. Production of IL-1β and TNFα
has also been found in IL-33-activated DCs that are associated
with allergic airway inflammation (26). Moreover, our DC2s did
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FIGURE 4 | IL-13, IFNγ, and IL-10 production by T-cells incubated with DC2s or DC1s, as measured by ELISA (A–C) and ratios of IL-13/IFNγ, IL-10/IL-13, and
IL-10/IFNγ compared between T-cells incubated with DC2s and T-cells incubated with DC1s (D–F). All treatments were compared with those of the DC2/T. All IL-13
measurements (A) are n = 7 independent donors, except for DC2, which are n = 3 independent donors. All IFNγ and IL-10 measurements are n = 5. Means ± SEM.
*p < 0.05; ***p < 0.001. DC, dendritic cell.
produce low levels of IL-13 (32–63 pg/ml), in line with previous
findings (25). Subsequently, the CD4+ T-cells incubated with
DC2s produced significantly higher levels of IL-13 and tended to
produce lower levels of IFNγ and IL-10 than did T-cells incubated
with DC1s, as previously described (25). Finally, as expected,
a higher IL-13/IFNγ ratio was observed in the supernatant
of T-cells incubated with DC2s compared with that of T-cells
incubated with DC1s. These findings indicate the expression of
OX40L by the DC2 cells leading to the subsequent production
of Th2 cytokine IL-13, which is a characteristic of DC2–T-
cell interactions. The results of this study could be verified by
comparing our findings to an assay using DCs and autologous
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FIGURE 5 | IL-13, IFNγ, and IL-10 production by T-cells incubated with DC2s treated with different PUFAs, as measured by ELISA (A–C) and ratios of IL-13, IFNγ,
and IL-10 compared between T-cells incubated with DC2s that were treated with different PUFAs (D–F). All treatments were compared with the NT (T-cells + DC2s).
Means ± SEM. All IL-13 measurements are n = 7 independent donors. All IFNγ and IL-10 measurements are n = 5. **p < 0.01; ***p < 0.001. DC, dendritic cell;
PUFA, polyunsaturated fatty acid.
T-cells derived from (food) allergic patients. In such a model,
allergen-specific responses could be investigated for different
types of allergies. As not all allergens are expected to be similarly
modulated, a next step would be to analyze allergen-specific
responses in our model. Altogether, the DC2–T-cell model might
be a promising in vitro tool for screening new components for the
prevention of Th2-driven inflammatory diseases. These types of
models may be more relevant to predict the effects of bioactive
components linked to an allergic setting than the DC–T-cell
models that make use of LPS-induced activation.
The mechanism behind the effects of PUFA in DC2–T-
cell activation remains unclear and needs further investigation.
Th2 cells are commonly polarized by IL-4. In vivo, many IL-4
producing cells could be responsible for Th2 cell polarization.
In an in vivo mouse model for ovalbumin (OVA)-induced food
allergy, it has been shown that basophils could play an important
role in IL-4-related polarization of Th2 cells in the sensitization
phase of allergy (27), which has also been found in vitro (28).
Furthermore, IL-4 production by MCs (29) and natural killer
(NK) T-cells (30) has also been described to play a role in Th2
polarization and allergy. However, even though these cytokines
were not added in the current set up and only low levels of IL-13
were measured in the DC supernatant, DC2s still were capable
of instructing IL-13 release by the developed Th-cells, indicating
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that other factors beyond IL-4 and IL-13 also in vivo may be
involved in development of Th2 driving DC.
The developed DC2-Th2 model was modulated by several
PUFAs. In DC2s treated with LCPUFA DHA, the surface
expression of OX40L was significantly lower than that of
untreated DC2s and not significantly different from that of
DC1s, indicating reduced DC2 development. This can also be
observed in IL-12p40 and IL-23 cytokine production of the DHA-
treated DC2s and reduced Th2 development as indicated by
lower IL-13 production of the T-cells. Furthermore, LCPUFAs
EPA (n−3) and AA (n−6) also significantly lower IL-12p40 and
IL-23 cytokine production by DC2s similar to DHA and show a
similar pattern in lowering T-cell-derived IL-13 secretion. In line
with these findings, EPA and DHA have both been previously
described to lower inflammatory cytokine production of DC1s
(15, 16). However, inhibition of costimulatory molecules CD80
and CD86 (15, 16) was not observed by these n−3 LCPUFA in
the DC2 model.
Surprisingly, AA was effective in lowering surface expression
of CD80 and CD83 in addition to lowering the secretion of
IL-12p40 and IL-23 by DC2s. Also in the subsequent DC2–T-
cell assays, the Th2 response as indicated by IL-13 production
was lowered by EPA and DHA and, although not significantly,
by AA. Furthermore, the IL-13/IL-10 ratios were shifted more
toward a regulatory IL-10 type of immune balance just like
n−3 LCPUFA EPA and DHA. IL-10 is a suppressive cytokine
that can be produced by several cell types, including regulatory
T-cells. Indeed, regulatory T-cells were found to prevent the
development of allergy in mice that were fed DHA-rich fish
oil (12). Oral tolerance induction in mice was reported to be
disrupted when an increasing dose of soy bean oil was provided,
which contains no AA but LA. This increasing dose of soy bean
oil was also found to increase the Th2/Th1 and Th2/Treg ratio,
indicating skewing toward a pro-allergic phenotype, which may
have facilitated allergic sensitization instead of oral tolerance
induction. In the erythrocyte membranes of these mice, the LA
levels increased, whereas AA remained unchanged (22). Indeed,
in the current study, LA tended to increase OX40L in the DC2s,
even though little difference was found in cytokine production
between untreated DC2s and LA-treated DC2s. In line with
this finding, we also observed a significantly higher IL-13/IFNγ
ratio produced by T-cells incubated with DC2s treated with LA,
indicating a shift toward a more Th2-type differentiation, as
previously reported in allergic mice fed increasing concentration
of LA-rich soybean oil (22). In conclusion, in vivo described
allergy-reducing DHA was found to lower OX40L surface
expression, and both EPA and DHA lowered IL-12p40 and IL-23
production by DC2s in association with less IL-13 production by
T-cells. Also, EPA and DHA enhanced the secretion of regulatory
type IL-10 secretion over Th2 and Th1 signature cytokines in
the in vitro allogeneic DC2/T-cell model. In addition, n−6 PUFA
LA tended to enhance Th2 driving OX40L expression on DC2
while enhancing the secretion of Th2-type IL-13 over Th1-
type IFNγ, identifying LA as a possible factor contributing to
allergic sensitization. By contrast, n−6 LCPUFA AA, similar to
DHA, tended to lower OX40L expression and, in addition, was
capable of lowering CD80 and CD83 costimulatory molecule
expression on DC2 when added during maturation and tipping
the balance toward a more regulatory-prone IL-10 response. This
could indicate that like EPA and DHA, also AA may be able to
lower the risk of allergic sensitization. Therefore, the developed
allogeneic DC2/T-cell model might be useful for future testing of
different anti-allergic bioactive components prior to testing them
in in vivo animal or human studies. Furthermore, AA should be
studied more extensively in vivo to further explore its potential
in lowering allergic sensitization, maybe in combination with
DHA in different ratios, as AA and DHA might compete in
membrane incorporation.
As allergy is becoming a rapidly increasing worldwide
problem, more tools are needed to investigate the allergic
sensitization phase to be able to test agents that may prevent
allergy from developing as the most important first step in allergy
management. In this study, the use of the allogeneic DC2/T-cell
model was shown as a promising model to investigate bioactive
agents on several markers known to be involved in the allergic
sensitization cascade (7). Not only n−3 LCPUFAs EPA and DHA
successfully suppressed DC2 maturation and the consequent
Th2-type IL-13 secretion by allogeneic T-cells. This effect was
also shown by n−6 LCPUFA AA, unlike n−3 PUFA ALA and
n−6 PUFA LA. This shows the discriminative capacity of this
assay to predict the allergy preventive effect and to identify
components that may be able to reduce allergic sensitization by
targeting DC2 development. Future studies should further reveal
the translational value of this model, for example, in in vivo
preclinical models of allergic sensitization.
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